Tissue | Expression Dynamics | Abbreviation |
Breast | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Breast/CD44_pca_on_diff_genes.png) | IDC: Invasive ductal carcinoma |
DCIS: Ductal carcinoma in situ |
Precancer(BRCA1-mut): Precancerous lesion from BRCA1 mutation carriers |
Cervix | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Cervix/CD44_pca_on_diff_genes.png) | CC: Cervix cancer |
HSIL_HPV: HPV-infected high-grade squamous intraepithelial lesions |
N_HPV: HPV-infected normal cervix |
Colorectum (GSE201348) | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Colorectum/Becker/CD44_pca_on_diff_genes.png) | FAP: Familial adenomatous polyposis |
CRC: Colorectal cancer |
Colorectum (HTA11) | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Colorectum/Chen/CD44_pca_on_diff_genes.png) | AD: Adenomas |
SER: Sessile serrated lesions |
MSI-H: Microsatellite-high colorectal cancer |
MSS: Microsatellite stable colorectal cancer |
Endometrium | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Endometrium/CD44_pca_on_diff_genes.png) | AEH: Atypical endometrial hyperplasia |
EEC: Endometrioid Cancer |
Esophagus | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Esophagus/CD44_pca_on_diff_genes.png) | ESCC: Esophageal squamous cell carcinoma |
HGIN: High-grade intraepithelial neoplasias |
LGIN: Low-grade intraepithelial neoplasias |
Liver | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Liver/CD44_pca_on_diff_genes.png) | HCC: Hepatocellular carcinoma |
NAFLD: Non-alcoholic fatty liver disease |
Lung | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Lung/CD44_pca_on_diff_genes.png) | AAH: Atypical adenomatous hyperplasia |
AIS: Adenocarcinoma in situ |
IAC: Invasive lung adenocarcinoma |
MIA: Minimally invasive adenocarcinoma |
Oral Cavity | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/OralCavity/CD44_pca_on_diff_genes.png) | EOLP: Erosive Oral lichen planus |
LP: leukoplakia |
NEOLP: Non-erosive oral lichen planus |
OSCC: Oral squamous cell carcinoma |
Prostate | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Prostate/CD44_pca_on_diff_genes.png) | BPH: Benign Prostatic Hyperplasia |
Skin | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Skin/CD44_pca_on_diff_genes.png) | AK: Actinic keratosis |
cSCC: Cutaneous squamous cell carcinoma |
SCCIS:squamous cell carcinoma in situ |
Thyroid | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Thyroid/CD44_pca_on_diff_genes.png) | ATC: Anaplastic thyroid cancer |
HT: Hashimoto's thyroiditis |
PTC: Papillary thyroid cancer |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:004206025 | Cervix | N_HPV | wound healing | 28/534 | 422/18723 | 3.37e-05 | 8.58e-04 | 28 |
GO:007233225 | Cervix | N_HPV | intrinsic apoptotic signaling pathway by p53 class mediator | 10/534 | 76/18723 | 5.77e-05 | 1.28e-03 | 10 |
GO:005134624 | Cervix | N_HPV | negative regulation of hydrolase activity | 25/534 | 379/18723 | 9.66e-05 | 1.97e-03 | 25 |
GO:190225325 | Cervix | N_HPV | regulation of intrinsic apoptotic signaling pathway by p53 class mediator | 6/534 | 29/18723 | 1.42e-04 | 2.65e-03 | 6 |
GO:190179625 | Cervix | N_HPV | regulation of signal transduction by p53 class mediator | 10/534 | 93/18723 | 3.17e-04 | 4.75e-03 | 10 |
GO:003158924 | Cervix | N_HPV | cell-substrate adhesion | 23/534 | 363/18723 | 3.24e-04 | 4.84e-03 | 23 |
GO:00704861 | Cervix | N_HPV | leukocyte aggregation | 4/534 | 13/18723 | 3.81e-04 | 5.49e-03 | 4 |
GO:200011624 | Cervix | N_HPV | regulation of cysteine-type endopeptidase activity | 17/534 | 235/18723 | 4.36e-04 | 6.01e-03 | 17 |
GO:002260424 | Cervix | N_HPV | regulation of cell morphogenesis | 20/534 | 309/18723 | 5.98e-04 | 7.85e-03 | 20 |
GO:007233125 | Cervix | N_HPV | signal transduction by p53 class mediator | 13/534 | 163/18723 | 8.20e-04 | 1.01e-02 | 13 |
GO:190216522 | Cervix | N_HPV | regulation of intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediator | 4/534 | 16/18723 | 9.06e-04 | 1.08e-02 | 4 |
GO:004277122 | Cervix | N_HPV | intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediator | 6/534 | 43/18723 | 1.30e-03 | 1.42e-02 | 6 |
GO:004328124 | Cervix | N_HPV | regulation of cysteine-type endopeptidase activity involved in apoptotic process | 14/534 | 209/18723 | 2.78e-03 | 2.42e-02 | 14 |
GO:190222922 | Cervix | N_HPV | regulation of intrinsic apoptotic signaling pathway in response to DNA damage | 5/534 | 36/18723 | 3.36e-03 | 2.74e-02 | 5 |
GO:00341141 | Cervix | N_HPV | regulation of heterotypic cell-cell adhesion | 4/534 | 26/18723 | 5.94e-03 | 4.16e-02 | 4 |
GO:190216611 | Cervix | N_HPV | negative regulation of intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediator | 3/534 | 14/18723 | 6.64e-03 | 4.45e-02 | 3 |
GO:007037121 | Cervix | N_HPV | ERK1 and ERK2 cascade | 18/534 | 330/18723 | 6.81e-03 | 4.53e-02 | 18 |
GO:000716013 | Cervix | N_HPV | cell-matrix adhesion | 14/534 | 233/18723 | 7.21e-03 | 4.74e-02 | 14 |
GO:000863022 | Cervix | N_HPV | intrinsic apoptotic signaling pathway in response to DNA damage | 8/534 | 99/18723 | 7.37e-03 | 4.80e-02 | 8 |
GO:0097193 | Colorectum | AD | intrinsic apoptotic signaling pathway | 108/3918 | 288/18723 | 6.25e-11 | 6.41e-09 | 108 |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
CD44 | SNV | Missense_Mutation | | c.106G>A | p.Val36Met | p.V36M | P16070 | protein_coding | deleterious(0) | probably_damaging(0.995) | TCGA-A2-A0ET-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | cytoxan | SD |
CD44 | SNV | Missense_Mutation | novel | c.1934C>T | p.Pro645Leu | p.P645L | P16070 | protein_coding | deleterious(0) | possibly_damaging(0.541) | TCGA-B6-A0I9-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Unknown | Unknown | PD |
CD44 | SNV | Missense_Mutation | | c.829G>C | p.Glu277Gln | p.E277Q | P16070 | protein_coding | tolerated(0.18) | benign(0.32) | TCGA-D8-A143-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | doxorubicin | SD |
CD44 | insertion | Nonsense_Mutation | novel | c.1935_1936insATCATATAATCTCAATGCAATAAATAATCAA | p.Gln646IlefsTer3 | p.Q646Ifs*3 | P16070 | protein_coding | | | TCGA-B6-A0I9-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Unknown | Unknown | PD |
CD44 | deletion | Frame_Shift_Del | | c.1454_1461delCAAATCCA | p.Ala485GlufsTer22 | p.A485Efs*22 | P16070 | protein_coding | | | TCGA-C8-A1HJ-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
CD44 | SNV | Missense_Mutation | novel | c.476N>C | p.Gly159Ala | p.G159A | P16070 | protein_coding | deleterious(0) | probably_damaging(0.987) | TCGA-DG-A2KM-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | SD |
CD44 | SNV | Missense_Mutation | | c.1521N>C | p.Gln507His | p.Q507H | P16070 | protein_coding | deleterious(0.02) | possibly_damaging(0.707) | TCGA-FU-A23K-01 | Cervix | cervical & endocervical cancer | Female | <65 | III/IV | Unknown | Unknown | SD |
CD44 | SNV | Missense_Mutation | rs371026548 | c.1289C>T | p.Ser430Leu | p.S430L | P16070 | protein_coding | deleterious(0.02) | benign(0.154) | TCGA-IR-A3LA-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
CD44 | SNV | Missense_Mutation | novel | c.1790N>C | p.Asn597Thr | p.N597T | P16070 | protein_coding | deleterious(0.01) | benign(0.025) | TCGA-VS-A9U5-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
CD44 | SNV | Missense_Mutation | | c.92N>T | p.Ala31Val | p.A31V | P16070 | protein_coding | deleterious(0) | benign(0.329) | TCGA-AA-A01I-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | SD |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
960 | CD44 | DRUGGABLE GENOME, CELL SURFACE | | GENTAMICIN | GENTAMICIN | 14967965 |
960 | CD44 | DRUGGABLE GENOME, CELL SURFACE | | MPA | PROGESTERONE | 11605071 |
960 | CD44 | DRUGGABLE GENOME, CELL SURFACE | | RG7356 | | 25762343 |
960 | CD44 | DRUGGABLE GENOME, CELL SURFACE | | TUMOR NECROSIS FACTOR | | 12867430 |
960 | CD44 | DRUGGABLE GENOME, CELL SURFACE | | GP-120 | | 7539755 |
960 | CD44 | DRUGGABLE GENOME, CELL SURFACE | | INTERFERON GAMMA | | 11369659 |
960 | CD44 | DRUGGABLE GENOME, CELL SURFACE | | HYALURONAN | HYALURONAN | |
960 | CD44 | DRUGGABLE GENOME, CELL SURFACE | | MOMETASONE FUROATE | | 12877820 |
960 | CD44 | DRUGGABLE GENOME, CELL SURFACE | | A-6 | | |
960 | CD44 | DRUGGABLE GENOME, CELL SURFACE | | BIWA 4 | | |